Asia Pacific Equity Research 20 June 2025 J P M O R G A N Mid-Year Prospects Healthcare This report forms part of the J.P. Morgan Australia Mid-Year Prospects series as we take stock at the mid-point of 2025 and set out our Top Picks and Least Preferred stocks for the remainder of the year. Top Pick – ResMed (RMD AU, OW) Earnings upside as sectoral trends pull forward demand Demand and diagnosis supported by industry tailwinds. Awareness of obstructive sleep apnoea is on the rise, supported by consumer mark ...

Company Overview - Beijing RMT Medical Technology Co., Ltd. was established in 2001 and successfully listed on the Shenzhen Stock Exchange's Growth Enterprise Market on November 1, 2022 [2] - The company specializes in providing comprehensive treatment solutions for OSA and COPD patients, focusing on home non-invasive ventilators and ventilation masks [2] - RMT is the first domestic company to have non-invasive ventilator products certified by the FDA, with sales in over 100 countries [2] Research and Development - As of December 31, 2024, the company holds 633 valid patents in China, including 107 invention patents, 390 utility model patents, and 136 design patents [3] - The company also has 202 valid overseas patents, including 39 in the United States and 30 in Europe [3] Financial Performance - In Q1 2025, the company's overseas revenue reached 170 million CNY, a year-on-year increase of 35.48%, while domestic revenue was 96 million CNY, with a quarter-on-quarter growth of 48.79% and a year-on-year growth of 43.03% [4] - The gross margin for domestic operations was 51.51%, and for overseas operations, it was 48.47%, with both showing an increase compared to the previous quarter [4] Product Launches and Market Strategy - The newly launched P5 series ventilators are primarily targeted at domestic hospital channels, which have a relatively high gross margin [4] - The introduction of the RMT oxygen bottle marks a strategic shift towards the consumer goods market, enhancing brand influence and market share [5] Brand Development - The company's rebranding to "RMT" signifies a strategic alignment between product and capital markets, aiming to enhance brand value [5] - The name "RMT" reflects the company's commitment to respiratory health and smart technology, creating a unified identity across products and capital markets [5] Market Expansion - The company has made adjustments to domestic channel policies and sales strategies, resulting in improved revenue and gross margins in Q1 2025 [5] - In Europe, the company has completed the construction of its cloud platform and is onboarding agents, laying the groundwork for future growth in the mainstream medical insurance market [5]

AdaptHealth (AHCO) 2025 Conference May 21, 2025 08:00 AM ET Speaker0 Relations in the room. Thank you guys very much for joining us. Thanks for having us, Ben. Yeah. I just wanted to kinda recap some of the dynamics that are going on in the quarter. Diabetes revenue declined 8%, but it's largely as expected. We're doing a overhaul of that segment, but you noticed some better than expected sequential developments and setups. Maybe you can kinda walk us through what you're seeing and and kinda how we you're f ...

AdaptHealth (AHCO) Q1 2025 Earnings Call May 06, 2025 08:30 AM ET Company Participants Suzanne Foster - Chief Executive Officer & DirectorJason Clemens - Chief Financial OfficerMeghan Holtz - VP, Healthcare Services Equity ResearchKevin Caliendo - Managing DirectorBen Hendrix - Vice PresidentMathew Blackman - Managing DirectorWhit Mayo - Senior Managing Director Conference Call Participants Pito Chickering - AnalystEric Coldwell - Senior Research AnalystJohn Pinney - Analyst Operator Good day, everyone, and ...

AdaptHealth (AHCO) Q1 2025 Earnings Call May 06, 2025 08:30 AM ET Speaker0 Good day, everyone, and welcome to today's Adapt Health's First Quarter twenty twenty five Earnings Release. Today's speakers will be Suzanne Foster, Chief Executive Officer of Adapt Health and Jason Clements, Chief Financial Officer of Adapt Health. Before we begin, I'd like to remind everyone that statements included in this conference call and in the press release issued today may constitute forward looking statements within the m ...

AdaptHealth Corp. (NASDAQ:AHCO) Q4 2024 Earnings Conference Call February 25, 2025 8:30 AM ET Company Participants Suzanne Foster – Chief Executive Officer Jason Clemens – Chief Financial Officer Conference Call Participants Ben Hendrix – RBC Capital Markets Mathew Blackman – Stifel Brian Tanquilut – Jefferies Richard Close – Canaccord Eric Coldwell – Baird Kieran Ryan – Deutsche Bank Operator Good day, everyone and welcome to today's AdaptHealth Fourth Quarter 2024 Earnings Release. Today's speakers will b ...